- It is estimated that one in 10 Mexicans lives with CKD and the death rate is 51 people per 100,000 inhabitants.
- One of the main problems is its late diagnosis due to the absence of symptoms in the early stages.
- Among the main risk factors are obesity, diabetes and high blood pressure.
The civil association specialized in prevention and clinical diagnosis, Salud Digna, and the global biopharmaceutical company, AstraZeneca, signed a collaboration agreement. The objective of this alliance is to promote the timely diagnosis and treatment of Chronic Kidney Disease in the Mexican population, which maintains a high incidence.
Achieve early detection in patients
As part of this union is sought grant free tests to people with risk factors for developing this disease. In this way they will be able to know the current state of their kidneys and identify any warning signs to be treated immediately.
In Mexico, the complications of chronic diseases such as diabetes and high blood pressure have a drastic impact on the health system. Among these complications is the Chronic Kidney Diseasewhich requires the generation of urgent strategies that help stop the progress of this disease.
The Chronic Kidney Disease It is one of the most prevalent Non-Communicable Diseases (NCDs) in the country. The Ministry of Health (SSa) estimates that one in 10 Mexicans lives with the disease. While the death rate due to chronicity and lack of care is 51 people per 100,000 inhabitants.
Main risk factors
It is essential that people who live with risk factors such as obesity, diabetes, high blood pressure and have a family history of Chronic Kidney Disease diagnostic tests and monitoring of kidney function to detect any abnormalities.
“We know that if this condition is detected early, we can prevent the progression of the disease and change people’s quality of life, avoiding procedures such as dialysis. At AstraZeneca we are aware of what it means for the health system to care for people at this stage. Therefore, in this collaboration with Salud Digna we will be able to help change the course of the disease,” said Julio Ordaz, director of AstraZeneca Mexico.
Although preventive measures for the most common causes of this disease, such as diabetes and high blood pressure, can reduce the need for replacement therapy with dialysis or kidney transplantation, there is still a long way to go to solve this problem, initially because of access.
The World Health Organization (WHO) points out that although the data currently available on access to treatment for this condition are insufficient to fully understand how to treat patients, they have served to analyze the inequity that exists on access to treatment, especially in lower-income countries.
“At AstraZeneca we are committed to working towards timely diagnosis, which is why we develop therapeutic solutions based on science and innovation with the aim of improving the quality of life of those who live with the condition. We are sure that with this collaboration we will improve the diagnosis and approach to the disease”, concluded Dr. Alberto Hegewisch, medical director of AstraZeneca Mexico.
Also read:
Chronic kidney disease may be more deadly in men than women
Diabetes, responsible for half of cases of chronic kidney disease in Mexico
SSa prepares national strategy to treat chronic kidney disease